866-997-4948(US-Canada Toll Free)

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 172 Pages

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD)-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD)-Pipeline Review, H2 2017, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that wont heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 13, 7, 10 and 2 respectively.

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Overview 8
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Products under Development by Companies 13
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Companies Involved in Therapeutics Development 23
AnGes MG Inc 23
AstraZeneca Plc 23
Athera Biotechnologies AB 24
Athersys Inc 24
Bayer AG 25
Betagenon AB 25
BiogenCell Ltd 26
CardioVascular BioTherapeutics Inc 26
Celgene Corp 27
Diffusion Pharmaceuticals Inc 27
Foresee Pharmaceuticals LLC 28
Hemostemix Inc 28
ID Pharma Co Ltd 28
Juventas Therapeutics Inc 29
LipimetiX Development Inc 29
Miragen Therapeutics Inc 30
Novartis AG 30
Nuo Therapeutics Inc 31
Proteon Therapeutics Inc 31
Recardio GmbH 32
Resverlogix Corp 32
Sigma-Tau SpA 33
Stemedica Cell Technologies Inc 33
Symic Biomedical Inc 33
VESSL Therapeutics Ltd 34
ViroMed Co Ltd 34
Yuyu Pharma Inc 35
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Drug Profiles 36
ACP-01-Drug Profile 36
AEM-28-Drug Profile 39
ALD-301-Drug Profile 41
alprostadil-Drug Profile 44
apabetalone-Drug Profile 46
BAY-1193397-Drug Profile 60
beperminogene perplasmid-Drug Profile 61
BGC-101-Drug Profile 66
Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases-Drug Profile 67
Cell Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease-Drug Profile 68
CVBT-141C-Drug Profile 69
Drug for Peripheral Arterial Disease-Drug Profile 70
DVC-10101-Drug Profile 71
ELS-140-Drug Profile 73
FP-045-Drug Profile 74
JVS-100-Drug Profile 75
levocarnitine propionate hydrochloride-Drug Profile 80
LLG-783-Drug Profile 81
MRG-110-Drug Profile 82
O-304-Drug Profile 84
PC-mAb-Drug Profile 86
PDA-002-Drug Profile 89
PF-05285401-Drug Profile 91
REC-03-Drug Profile 103
Rejuveinix-Drug Profile 104
rivaroxaban-Drug Profile 105
SB-030-Drug Profile 122
Stem Cell Therapy for Cardiovascular Disease, Central Nervous System Disorders, Infectious Diseases, Respiratory and Metabolic Disorders-Drug Profile 124
transcrocetinate sodium-Drug Profile 129
TXA-127-Drug Profile 134
TXA-302-Drug Profile 138
V-10-Drug Profile 139
VM-202-Drug Profile 140
vonapanitase-Drug Profile 144
YY-984-Drug Profile 150
zibotentan-Drug Profile 151
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects 153
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Discontinued Products 156
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Product Development Milestones 157
Featured News & Press Releases 157
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 169
Disclaimer 170

List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by AnGes MG Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by AstraZeneca Plc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Athera Biotechnologies AB, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Athersys Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Bayer AG, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Betagenon AB, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by BiogenCell Ltd, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by CardioVascular BioTherapeutics Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Celgene Corp, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Diffusion Pharmaceuticals Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Foresee Pharmaceuticals LLC, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Hemostemix Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by ID Pharma Co Ltd, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Juventas Therapeutics Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by LipimetiX Development Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Miragen Therapeutics Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Novartis AG, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Nuo Therapeutics Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Proteon Therapeutics Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Recardio GmbH, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Resverlogix Corp, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Sigma-Tau SpA, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Stemedica Cell Technologies Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Symic Biomedical Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by VESSL Therapeutics Ltd, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by ViroMed Co Ltd, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Yuyu Pharma Inc, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects, H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects, H2 2017 (Contd..1), H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects, H2 2017 (Contd..2), H2 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *